Circadian developmental rhythms of the experimental paracetamol hepatitis and the effect of hepatoprotectors on the activity of pro-oxidative / antioxidant and cytolytic processes
DOI:
https://doi.org/10.24959/cphj.19.1485Keywords:
circadian rhythms, hepatoprotectors, paracetamol hepatitis, silymarin, antral, carsil, arginine glutamateAbstract
One of the current trends in modern experimental and clinical pharmacology is determination of the dependence of the effectiveness and toxicity of drugs on the time of day or season of the year.
Aim. To determine the characteristics of circadian rhythms of modern hepatoprotectors on the balance of antioxidant / prooxidant processes and the activity of cytolysis under conditions of acute paracetamol hepatitis in rats.
Materials and methods. Acute toxic hepatitis was caused by a single oral administration of paracetamol in the dose of 1000 g/kg of the body weight of animals in the morning (09.00), day (15.00), evening (21.00) and night (03.00) periods. In order to describe the effect on the lipid peroxidation/antioxidant system the intensity of the lipid peroxidation was measured by the level of tiobarbituric acid active products (TBA-AP). Determination of the level of recovered glutathione (RG), superoxide dismutase (SOD) and the catalase activity in the liver homogenate allowed characterizing the functional state of the antioxidant system of the animal organism. The activity of cytolytic processes was determined by the level of alanine aminotransferase (ALT) cytolysis marker in the blood serum.
Results. The circadian mass peak of the activity of the antioxidant system of the liver under physiological conditions in rats in the morning-day time and the minimum activity in the evening-night were determined. The experimental paracetamol hepatitis was characterized by peaks of the cytolytic process activity in the evening (21.00) and in the morning (09.00). The increase in the ALT activity by 3.3 and 2.5 times (p<0.05) coincides with a peak reduction of endogenous antioxidant (RG) in the morning by 1.4 times (p<0.05) and the minimal cytolytic changes during the day (15.00) and at night (03.00). It was found that there was the most marked effect of the phytohepatoprotector silymarin (carsil) and the synthetic hepatoprotector antral on the balance of antioxidant / prooxidant and cytolytic processes in the morning (09.00) and evening (21.00). It was confirmed by an increase in the level of RG by 1.2 times (p<0.05) and a decrease in the activity of ALT by 1.2-1.5 times (p<0.05) in relation to animals with hepatitis when using silymarin, as well as an increase in the SOD activity by 1.2 times (p<0.05), an increase in the level of RG by 1.3 and 1.4 times and a decrease in the activity of ALT by 1.3-1.5 times (p<0.05) when using antral. Arginine glutamate (“Glutargin”) increased the activity of the antioxidant system and suppressed cytolytic processes during the day (15.00) and at night (03.00) against the background of paracetamol hepatitis: an increase in the level of RG by 1.4 times (p<0.05) and a decrease in the activity of ALT in 1.2-1.3 times (p<0.05), respectively.
Conclusions. The circadian rhythms of the maximum severity of paracetamol hepatitis determined (at 21.00 and 09.00) should be taken into account in the experimental pharmacology when reproducing this model of liver damage. The antioxidant and anticytolytic action of silymarin and antral is maximally detected in the morning and evening, while the effect of arginine glutamate revealed during the day and at night. The chronopharmacological peculiarities of the effect of the hepatoprotectors studied on antioxidant / prooxidant and cytolytic processes should be taken into account when using them as reference values in the preclinical study of promising hepatoprotectors and in further chronopharmacological studies.
References
Drogovoz, S. M. (2016). Khronofarmakologiia dlia vracha, provizora, studenta: uchebnik-spravochnik. Kharkiv: Titul, 376.
Dallmann, R., Brown, S. A., & Gachon, F. (2014). Chronopharmacology: New Insights and Therapeutic Implications. Annual Review of Pharmacology and Toxicology, 54(1), 339–361. https://doi.org/10.1146/annurev-pharmtox-011613-135923
Kharchenko, N. V., Anokhina, G. A., Korulia, I. A., Chervak, I. N. (2015). Suchasna gastroenterologіia, 4, 43–50.
Kalko, K. O. (2017). Khronofarmakolohichne doslidzhennia aktyvnosti hepatoprotektornykh zasobiv: Doctor’s thesis. NFaU. Kharkiv, 187.
Bueverov, A. O. (2012). RMZh, 3, 107–111.
Kharchenko, N. V., Anokhina, H. A., Chekman, S. I., Korulia, I. A., Kharchenko, V. V. (2013). Zdorov’ia Ukrainy, 5, 28–29.
McDonnell, M. E., Braverman, L. E. (2006). Drug-Related Hepatotoxicity. New England Journal of Medicine, 354(20), 2191–2193. https://doi.org/10.1056/nejmc060733
Drogovoz, S. M., Gudzenko, A. P., Butko, Ia. A. (2015). Pobochnoe deistvie lekarstv: uchebnik-spravochnik. Kharkov: «SIM», 480.
Caparrotta, T. M., Antoine, D. J., & Dear, J. W. (2017). Are some people at increased risk of paracetamol-induced liver injury? A critical review of the literature. European Journal of Clinical Pharmacology, 74(2), 147–160. https://doi.org/10.1007/s00228-017-2356-6
Bateman, D. N., Carroll, R., Pettie, J., Yamamoto, T., Elamin, M., Peart, L., …Dow, M. (2014). Effect of the UK's revised paracetamol poisoning management guidelines on admissions, adverse reactions and costs of treatment. British Journal of Clinical Pharmacology, 78(3), 610–618. https://doi.org/10.1111/bcp.12362
Mowry, J. B., Spyker, D. A., Cantilena, L. R., McMillan, N., & Ford, M. (2014). 2013 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 31st Annual Report. Clinical Toxicology, 52(10), 1032–1283. https://doi.org/10.3109/15563650.2014.987397
Craig, D. G. N., Bates, C. M., Davidson, J. S., Martin, K. G., Hayes, P. C., & Simpson, K. J. (2012). Staggered overdose pattern and delay to hospital presentation are associated with adverse outcomes following paracetamol-induced hepatotoxicity. British Journal of Clinical Pharmacology, 73(2), 285–294. https://doi.org/10.1111/j.1365-2125.2011.04067.x
Ferner, R. E., Dear, J. W., & Bateman, D. N. (2011). Management of paracetamol poisoning. BMJ, 342(2), 2218–2218. https://doi.org/10.1136/bmj.d2218
Ore, A., & Akinloye, O. A. (2019). Oxidative Stress and Antioxidant Biomarkers in Clinical and Experimental Models of Non-Alcoholic Fatty Liver Disease. Medicina, 55(2), 26. https://doi.org/10.3390/medicina55020026
Lee, Y.-S., Cho, I. J., Kim, J. W., Lee, M.-K., Ku, S. K., Choi, J.-S., & Lee, H.-J. (2018). Hepatoprotective effects of blue honeysuckle on CCl4-induced acute liver damaged mice. Food Science & Nutrition, 7(1), 322–338. https://doi.org/10.1002/fsn3.893
Kovalenko, V. N. (2015). Kompendium 2015 – lekarstvennye preparaty. Kyiv: Morion, 1408.
Derzhavnyi reiestr likarskykh zasobiv. (n.d.). Available at: http://www.drlz.com.ua/
Mokhort, M. A., Seredynska, M. N., Kyrychok, L. M. (2012). Zhurnal NAMN Ukrainy, 2, 152–160.
Frolov, V. M. (2003). Novosti meditciny i farmatcii, 8, 5–6.
Mironov, A. N. (2012). Rukovodstvo po provedeniiu doklinicheskikh issledovanii lekarstvennykh sredstv. Moscow: Grif i K, 944.
Chernadchuk, S. S. (2010). Metodicheskie ukazaniia dlia vypolneniia eksperimentalnykh issledovanii po bolshomu spetcialnomu praktikumu «Metody otcenki sostoianiia oksidantnoi i antioksidantnoi sistem biologicheskikh obektov». Odessa, 52.
Stalnaia I. D., Garishvili T. G. (1977). Sovremennye metody v biokhimii. Moscow: Meditcina, 44–46.
Koroliuk, M. A. (1988). Laboratornoe delo, 1, 16–19.
Sirota, T. V. (1999). Voprosy meditcinskoi khimii, 3, 263–272.
Kamyshnikova, V. S. (2015). Klinicheskaia laboratornaia diagnostika (metody i traktovka laboratornykh issledovanii). Moscow: MED-press-inform, 720.
Trukhacheva, N. V. (2012). Matematicheskaia statistika v mediko-biologicheskikh issledovaniiakh s primeneniem paketa Statistica. Moscow: GEOTAR-Media, 379.
Stefanov, O. V. (2001). Doklinichni doslidzhennia likarskykh zasobiv. Kyiv: Avitsena, 528.
Bunchorntavakul, C., & Reddy, K. R. (2013). Acetaminophen-related Hepatotoxicity. Clinics in Liver Disease, 17(4), 587–607. https://doi.org/10.1016/j.cld.2013.07.005
Rousar, T., Kucera, O., Kriváková, P., Lotková, H., Kandár, R., Muzáková, V., Cervinková, Z. (2009). Evaluation of oxidative status in acetaminophen treated rat hepatocytes in culture. Physiol Res, 58(2), 239–246.
Kalko, K. O., Drogovoz, S. M., Zakharko, N. V., Yudkevich, T. K. (2016). Farmakolohiia ta likarska toksykolohiia, 1 (47), 81–87.
Kalko, E. A., Drogovoz, S. M., Pozdniakova, A. Iu., & Zakharko, N. V. (2016). Eksperimentalnaia i Klinicheskaia Farmakologiia, 79(7), 25–28. https://doi.org/10.30906/0869-2092-2016-79-7-25-28
Kalko, K. O., Drohovoz, S. M. (2017). Farmakolohiia ta likarska toksykolohiia, 2 (53), 62–68.
Matveev, A. V. (2013). Gepatoprotektory. Analiz mezhdunarodnykh issledovanii po preparatam gruppy lekarstv dlia pecheni. Simferopol: IT «Arial», 384.
Yang, Z., Zhuang, L., Lu, Y., Xu, Q., & Chen, X. (2014). Effects and Tolerance of Silymarin (Milk Thistle) in Chronic Hepatitis C Virus Infection Patients: A Meta-Analysis of Randomized Controlled Trials. BioMed Research International, 2014, 1–9. https://doi.org/10.1155/2014/941085
Vargas-Mendoza, N. (2014). Hepatoprotective effect of silymarin. World Journal of Hepatology, 6(3), 144. https://doi.org/10.4254/wjh.v6.i3.144
Sakharova, T. S. (1989). “Poisk i farmakologicheskoe izuchenie gepatozashchitnykh sredstv v riadu metallokompleksov proizvodnykh N-fenilantranilovykh kislot”: Doctor’s thesis. NFaU. Kharkov, 197.
Downloads
Published
Issue
Section
License
Copyright (c) 2019 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
